Samheiti: á líka við AML-NOPHO (diagnose T-ALL eða AML) MRD Flow, ALL-NOPHO 2008, ALL2008 NOPHO MRD analyser,
Sýnataka, geymsla og sýnasending
Gerð sýnis : Mergur og/eða blóð (stundum mænuvökvi)
Sýni tekið í glas með fjólubláum tappa án gels (svört miðja) 
. Litakóði samkvæmt Greiner.
Magn: 10 ml ( Blóð 5-10 ml, mergur 5 ml)
Geymsla sýnis: Kælir / stofuhiti.
Sýnasending: Hraðsending til útlanda.
Heimildir
| Rekvirering: | Sundhedsplatformen/Rekvisitionsseddel |
| Laboratorium: | Rigshospitalet Blegdamsvej, Klinisk Immunologisk Afdeling, Vævstypelaboratoriet 7631 |
| Analysegruppe/Ansvarlig: | VTL 76-3-1 |
| Seneste gennemgang - Initialer : | 29/10/2019 - TWT |
| IFCC-IUPAC-kode og navn: | DNK35920 Marv—Leukæmi-restsygdom; fr.(diagnostisk immungenrearrangement (målt med RQ-PCR)) = ? |
| Synonymer: | MRD, MRD-PCR, PCR-MRD, Minimal restsygdom, Minimal restsygdomsmåling, Minimal Residual Disease. |
| Beskrivelse: | Real time kvantitativ PCR, iht. guidelines for EUROMRD |
| Indikation: | ALL patienter (herunder børn og voksne, der behandles efter NOPHO-protokol)
• T-ALL behandlingsmonitorering
• Infant ALL behandlingsmonitorering
• B-ALL behandlingsmonitorering, specielt ved dårlig MRD-flow markør
Obs relaps (af ALL eller anden sygdom med kendt MRD-PCR markør)
Relapsmonitorering (incl. børn behandlet efter IntReALL2010 protokol)
NHL behandlingsmonitorering
CLL behandlingsmonitorering
MRD kontrol før SCT (af sygdom med kendt MRD-PCR markør)
MRD kontrol efter SCT (af sygdom med kendt MRD-PCR markør) |
| Akkrediteret analyse: | DANAK |
| Metodeopsætning: |  |
| CE-mærket analyseopsætning: | |
| Mutationdetektionsprincip: | Real time kvantitativ PCR, iht. guidelines for EUROMRD |
| Metrologisk sporbarhed: | |
| Prøvemateriale: | Marv |
| Alternativt prøvemateriale: | |
| Prøvetagningsrør (Labka): | 1 stk Lilla9S. (K3-EDTA) |
| Prøvemængde: | 5 ml. |
| Opbevaring: | Prøven skal være på Vævstypelaboratoriet hurtigst muligt og senest 24 timer efter prøvetagning. |
| Må sendes med rørpost: | Nej |
| Svartid: | 4-10 arbejdsdage.
Hastesvar: 3 dage. |
| Ekstern kvalitetskontrol: | |
| Svartid: | |
| Svarmuligheder: | |
|
|
|
| Henvisning: | Kontakt Vævstypelaboratoriet på tlf. 3545 7631. |
| Gyldig fra: | 08/12/2015 |
| Gyldig til: | |
|
|
20170126T092125.pdf 
20170126T101004.pdf
Fróðleikur:
Minimal residual disease (MRD) is the name given to small numbers of leukaemic cells (cancer cells from the bone marrow) that remain in the patient during treatment, or after treatment when the patient is in remission (no symptoms or signs of disease). It is the major cause of relapse in cancer and leukemia. Up until a decade ago,[when?] none of the tests used to assess or detect cancer were sensitive enough to detect MRD. Now, however, very sensitive molecular biology tests are available, based on DNA, RNA or proteins. These can measure minute levels of cancer cells in tissue samples, sometimes as low as one cancer cell in a million normal cells.
In cancer treatment, particularly leukaemia, MRD testing has several important roles: determining whether treatment has eradicated the cancer or whether traces remain, comparing the efficacy of different treatments, monitoring patient remission status as well as detecting recurrence of the leukaemia or cancer, and choosing the treatment that will best meet those needs .
The tests are not simple, are often part of research or trials, and some have been accepted for routine clinical use.